Point Roberts WA, NEW YORK, NY -- June 25, 2015 -
Investorideas.com, a global news source covering leading sectors including biotech
and medical technology issues a media alert for Vycor Medical, Inc (OTCQB:VYCO) and its NovaVision Vision
Restoration Therapy. The company was recently featured in articles by Jim
Collins, Portfolio Guru, LLC, published at TheStreet.com.
Articles:
An Eye for EYES, and Here's Why
TheStreet.com-Jun 19, 2015
Jim Collins
Today I'll return to one of my favorite ideas, Second Sight Medical ...
I'll focus on another company in the vision field, Vycor Medical (VYCO). http://realmoney.thestreet.com/articles/06/19/2015/eye-eyes-and-heres-why
Follow up Article: Vycor Medical Offers Upside Through Vision Therapy
Jim Collins
Portfolio Guru, LLC
www.theportfolioguru.com
I wrote in Friday's column about Second Sight, whose Argus II retinal
implant restores sight in patients with retinitis pigmentosa and will soon
enter clinical trials for age-related macular degeneration. Both conditions are
obviously degenerative, but what happens when sight is impaired due to a sudden
condition? Two common causes of this would be stroke and traumatic brian injury
(TBI).
That's where Vycor Medical (VYCO) comes in. The company's NovaVision
suite of therapies offer ability to improve quality of vision--and thus quality
of life--in patients who have suffered stroke or TBI.
Link to article:
Read this release in full at http://www.investorideas.com/CO/VYCO/news/2015/06252.asp
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL,
Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB—VYCO)
dedicated to providing the medical community with innovative and superior
surgical and therapeutic solutions and has a growing portfolio of FDA cleared
medical solutions that are changing and improving lives every day. The Company
operates two business units: Vycor Medical and NovaVision, both of which adopt
a minimally or non-invasive approach. Both technologies have exceptional sales
growth potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
Vycor Medical’s ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive disposable devices
that hold the potential for speedier, safer and more economical brain surgeries
and a quicker patient discharge. VBAS is designed to optimize
neurosurgical site access, reduce patient risk, accelerate recovery and add
tangible value to the professional medical community. The company is ISO 13485:2003
compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full
regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU
– Class III), Korea and Japan and is seeking or has partial regulatory
approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor
Medical’s VBAS see VBAS Video.
NovaVision develops and provides science-driven
neurostimulation therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision impairments. The company’s proprietary Visual Restoration
Therapy® (VRT) platform is clinically supported to improve lost vision
resulting from Stroke, Traumatic Brain Injury (TBI), or other acquired brain
injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at
the restoration of vision for neurologically induced vision loss and can be
prescribed by any physician. VRT also
has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in
the EU, aimed at increasing visual sensitivity deep within the field defect.
The Company has also developed NeuroEyeCoach™, a
therapy which is highly complementary to VRT™. The two therapies address different visual disabilities each
of which results from neurologically-induced vision loss – a loss of visual
field as well as difficulty with eye movement, affecting the ability to
integrate visual information. VRT provides partial restoration of the patient’s
lost visual field; NeuroEyeCoach™ is designed to increase the efficiency of eye
movement and re-train the patients’ ability to integrate visual information
between the left and right hand side.
See the video on YouTube.com - NovaVision Vision
Restoration Therapy
For the latest information on the company,
including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.
InvestorIdeas.com
newswire is a global investor news source covering leading sectors including
medical technology and biotech.
Sign up for free news alerts at
Investorideas.com
Become an Investorideas.com Member and access our online stock
directories listing thousands of publicly traded stocks in leading sectors
Disclaimer/
Disclosure: The Investorideas.com newswire is a third party publisher of news
and research as well as creates original content as a news source. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Investorideas is a news source on Google news syndication
partners. Our site does not make recommendations for purchases or sale of stocks
or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
(VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media
and news distribution: Five thousand per month, one month with option to renew.
BC Residents and
Investor Disclaimer : Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new disclosure
filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
. Global investors must adhere to regulations of each country.
Contact Investorideas.com
800 665 0411
No comments:
Post a Comment